Dr Jeremy Steele is a highly esteemed consultant oncologist at Barts Health NHS Trust, specialising in lung cancer and malignant mesothelioma. He received his medical education at the University of London St George's Hospital Medical School and further honed his expertise in cancer medicine at the Royal Marsden Hospital. Dr Steele's extensive training also includes acute general medical specialties and intensive care medicine.

Dr Steele earned his Doctor of Medicine degree for his groundbreaking research on cancer biology, focusing on lung cancer, brain tumours, and childhood leukaemia. He further advanced his oncology training at St. Bartholomew's Hospital and the Royal London Hospital. In 1999, he expanded his knowledge internationally as a visiting fellow at Harvard Medical School's thoracic oncology centre in Boston.

In 2002, Dr Steele joined Barts Health NHS Trust, where he has since been a pivotal figure in the field of oncology. He is particularly renowned for his work in lung cancer and mesothelioma, having led one of the first effective clinical studies of mesothelioma therapy in East London. His contributions have significantly impacted the treatment landscape for these conditions.

Dr Steele is globally recognised as an expert in the diagnosis and treatment of malignant mesothelioma. He serves as the secretary of the International Mesothelioma Group (iMig) in Chicago and is the chairman of the advisory board for the Mesothelioma UK Charitable Trust. His dedication to patient advocacy is evident through his successful lobbying efforts with the UK Government to ensure the availability of novel cancer medicines.

Dr Steele's areas of expertise include malignant mesothelioma (both pleural and peritoneal), immunotherapy for mesothelioma and lung cancer, and maximising quality of life for his patients. He is a strong proponent of patient-centred cancer care, ensuring that each patient receives tailored and compassionate treatment.

Appointed as a consultant oncologist in 2002, Dr Steele continues to be a leading figure in oncology, contributing to both clinical practice and research. His commitment to advancing cancer treatment and improving patient outcomes remains unwavering.